The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas

ABSTRACT Introduction: Many RNA species have been identified as important players in the development of chronic diseases including cancer. Certain classes of regulatory RNAs such as microRNAs (miRNAs) have been investigated in such detail that bona fide tumor suppressive and oncogenic miRNAs have been identified. Because of this, there has been a major effort to therapeutically target these small RNAs. One in particular, a liposomal formulation of miR-34a (MRX34), has entered Phase I trials. Areas covered: This review aims to summarize miRNA biology, its regulation within normal versus disease states and how it can be targeted therapeutically, with a particular emphasis on miR-34a. Understanding the complexity of a single miRNA will aid in the development of future RNA-based therapeutics for a broader range of chronic diseases. Expert opinion: The potential of miRNAs to be developed into anti-cancer therapeutics has become an increasingly important area of research. miR-34a is a tumor suppressive miRNA across many tumor types through its ability to inhibit cellular proliferation, invasion and tumor sphere formation. miR-34a also shows promise within certain in vivo solid tumor models. Finally, as miR-34a moves into clinical trials it will be important to determine if it can further sensitize tumors to certain chemotherapeutic agents.

[1]  L. Kastl,et al.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[2]  Xiuping Liu,et al.  Epigenetic regulation of miR-34a expression in alcoholic liver injury. , 2012, The American journal of pathology.

[3]  Zhongwei Lv,et al.  MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. , 2013, DNA and cell biology.

[4]  T. Deguchi,et al.  MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms , 2010, The Prostate.

[5]  Laisheng Li,et al.  MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1 , 2013, Clinical and Experimental Medicine.

[6]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[7]  H. Hermeking,et al.  Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer , 2012, Clinical Cancer Research.

[8]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A W Langerak,et al.  17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation , 2009, Leukemia.

[10]  M. Houshmand,et al.  Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis , 2013, Medical Oncology.

[11]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[12]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[13]  F. Sarkar,et al.  Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF , 2012, Journal of Hematology & Oncology.

[14]  Bernat Gel,et al.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.

[15]  X J Li,et al.  MicroRNA-34a: a potential therapeutic target in human cancer , 2014, Cell Death and Disease.

[16]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[17]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[18]  F. Slack,et al.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. , 2012, Cancer research.

[19]  Joana A. Vidigal,et al.  Intact p53-Dependent Responses in miR-34–Deficient Mice , 2012, PLoS genetics.

[20]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[21]  R. Stallings,et al.  MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. , 2009, Current pharmaceutical design.

[22]  Natasha J. Caplen,et al.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA , 2011, Breast Cancer Research and Treatment.

[23]  S. Bohlander,et al.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. , 2010, Blood.

[24]  D. R. Laybutt,et al.  Alterations in MicroRNA Expression Contribute to Fatty Acid–Induced Pancreatic β-Cell Dysfunction , 2008, Diabetes.

[25]  Xiling Shen,et al.  A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. , 2013, Cell stem cell.

[26]  S. Xiong,et al.  MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. , 2012, Experimental cell research.

[27]  Bin Zhou,et al.  The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer , 2012, Medical Oncology.

[28]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[29]  A. Luo,et al.  MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1 , 2013, Oncogene.

[30]  D. Brown,et al.  Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer , 2014, Molecular Cancer Therapeutics.

[31]  A. Bouchie.  First microRNA mimic enters clinic , 2013, Nature Biotechnology.

[32]  F. Gao,et al.  The impact of miR‐34a on protein output in hepatocellular carcinoma HepG2 cells , 2010, Proteomics.

[33]  P. Birembaut,et al.  Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway , 2011, Nature Cell Biology.

[34]  J. Lieberman,et al.  miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. , 2009, Blood.

[35]  Š. Pospíšilová,et al.  miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities , 2009, Leukemia.

[36]  B. Verdoodt,et al.  Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas , 2011, Virchows Archiv.

[37]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[38]  H. Rehrauer,et al.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. , 2011, Blood.

[39]  X. Chen,et al.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. , 2015, Cellular signalling.

[40]  Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells. , 2014, Biomaterials.

[41]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[42]  K. Kelnar,et al.  In-Depth Analysis Shows Synergy between Erlotinib and miR-34a , 2014, PloS one.

[43]  E. Elkord,et al.  Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity , 2012, Clinical & developmental immunology.

[44]  Aamir Ahmad,et al.  Novel strategies targeting cancer stem cells through phytochemicals and their analogs , 2012, Drug Delivery and Translational Research.

[45]  R. Greil,et al.  Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia , 2010, Cell cycle.

[46]  Lin He,et al.  miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110 , 2014, Nature.

[47]  John J. Rossi,et al.  Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy , 2014, Molecular therapy. Nucleic acids.

[48]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[49]  Zhaoli Chen,et al.  DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer , 2011, Cancer biology & therapy.

[50]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[51]  Shunsuke Noguchi,et al.  Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. , 2011, Cancer letters.

[52]  M. Peter,et al.  CD95 Is Part of a Let-7/p53/miR-34 Regulatory Network , 2012, PloS one.

[53]  Qiang Yu,et al.  miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. , 2009, Genes & development.

[54]  M. Dong,et al.  Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF , 2014, Digestive Diseases and Sciences.

[55]  Yasunori Fujita,et al.  Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.

[56]  T. Mandrup-Poulsen,et al.  Altering β-cell number through stable alteration of miR-21 and miR-34a expression , 2014, Islets.

[57]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[58]  Sweta Rani,et al.  miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression , 2014, The Prostate.

[59]  Y. Qi,et al.  MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4 , 2014, Expert opinion on therapeutic targets.

[60]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[61]  Cizhong Jiang,et al.  MicroRNA-449 and MicroRNA-34b/c Function Redundantly in Murine Testes by Targeting E2F Transcription Factor-Retinoblastoma Protein (E2F-pRb) Pathway* , 2012, The Journal of Biological Chemistry.

[62]  Liang Zhou,et al.  MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment , 2014, Technology in cancer research & treatment.

[63]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[64]  S. Oltjen,et al.  Age-dependent increase in miRNA-34a expression in the posterior pole of the mouse eye , 2014, Molecular vision.

[65]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[66]  Junjiang Fu,et al.  MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. , 2014, Cancer letters.

[67]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[68]  Wei Yan,et al.  Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis , 2014, Proceedings of the National Academy of Sciences.

[69]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[70]  F. Slack,et al.  A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer , 2014, Oncogene.

[71]  Gregory J. Hannon,et al.  microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.

[72]  Erik Vassella,et al.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner , 2011, Molecular Cancer.

[73]  E. Song,et al.  Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. , 2014, Cancer research.

[74]  Naoto Tsuchiya,et al.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells , 2007, Proceedings of the National Academy of Sciences.

[75]  D. Xiang,et al.  Mir-34a Is Upregulated during Liver Regeneration in Rats and Is Associated with the Suppression of Hepatocyte Proliferation , 2011, PloS one.

[76]  Gozoh Tsujimoto,et al.  MicroRNA-34a Inhibits Cell Proliferation by Repressing Mitogen-Activated Protein Kinase Kinase 1 during Megakaryocytic Differentiation of K562 Cells , 2010, Molecular Pharmacology.

[77]  Wang Sheng,et al.  Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. , 2014, Biomaterials.

[78]  V. Bours,et al.  Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR‐34a and miR‐122 Expression , 2014, Journal of cellular physiology.

[79]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[80]  W Caron.  [Breast cancer: introduction]. , 1970, Laval medical.

[81]  R. Greil,et al.  Fatty acids trigger mitochondrion-dependent necrosis , 2010 .

[82]  S. Zhong,et al.  MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. , 2012, Archives of medical research.

[83]  N. Miller,et al.  Circulating miR‐34a levels are reduced in colorectal cancer , 2012, Journal of surgical oncology.

[84]  D. Lodygin,et al.  IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. , 2014, The Journal of clinical investigation.

[85]  Xing Chen,et al.  MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. , 2014, Cancer letters.

[86]  Anders Krogh,et al.  miR-449 inhibits cell proliferation and is down-regulated in gastric cancer , 2011, Molecular Cancer.

[87]  Y. Akao,et al.  Extracellular Disposal of Tumor-Suppressor miRs-145 and -34a via Microvesicles and 5-FU Resistance of Human Colon Cancer Cells , 2014, International journal of molecular sciences.

[88]  Frank J. Slack,et al.  Aberrant Regulation and Function of MicroRNAs in Cancer , 2014, Current Biology.

[89]  I. Pogribny,et al.  Down‐regulation of the microRNAs miR‐34a, miR‐127, and miR‐200b in rat liver during hepatocarcinogenesis induced by a methyl‐deficient diet , 2009, Molecular carcinogenesis.

[90]  Kai-Fu Tang,et al.  MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. , 2012, Carcinogenesis.

[91]  Jun Tang,et al.  Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  J. Chang-Claude,et al.  Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. , 2013, Clinical chemistry.

[93]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[94]  F. Slack,et al.  Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation , 2015, Cell cycle.

[95]  F. Slack,et al.  The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells , 2009, Oncogene.

[96]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[97]  A. Yadav,et al.  Dysregulation of MicroRNA-34a Expression in Head and Neck Squamous Cell Carcinoma Promotes Tumor Growth and Tumor Angiogenesis , 2012, PloS one.

[98]  Masahiko Kushida,et al.  Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. , 2011, Toxicology letters.

[99]  Can Liu,et al.  The microRNA miR-34a Inhibits Non-Small Cell Lung Cancer (NSCLC) Growth and the CD44hi Stem-Like NSCLC Cells , 2014, PloS one.

[100]  M. Mann,et al.  miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. , 2002, Genes & development.

[101]  Martin L. Smith,et al.  Regulation of the c-met Proto-oncogene Promoter by p53* , 1999, The Journal of Biological Chemistry.

[102]  Christopher J. Cheng,et al.  MicroRNA silencing for cancer therapy targeted to the tumor microenvironment , 2014, Nature.

[103]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[104]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.